Treatment with the CTGF antisense oligonucleotide reduced expression of genes involved in matrix expansion (fibronectin, collagen I and IV), and of an inhibitor of matrix degradation in the renal cortex, thus contributing to a significant reversal of mesangial expansion in two experimental models of diabetic nephropathy [46]. This evidence concerns the gene FN1 and diabetic kidney disease.